- Home
- HFRO vs FDMT Comparison
HFRO vs FDMT Comparison
Compare HFRO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- FDMT
- Stock Information
- Founded
- HFRO 2000
- FDMT 2013
- Country
- HFRO United States
- FDMT United States
- Employees
- HFRO N/A
- FDMT N/A
- Industry
- HFRO Finance/Investors Services
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- FDMT Health Care
- Exchange
- HFRO Nasdaq
- FDMT Nasdaq
- Market Cap
- HFRO 402.7M
- FDMT 420.7M
- IPO Year
- HFRO N/A
- FDMT 2020
- Fundamental
- Price
- HFRO $5.43
- FDMT $8.83
- Analyst Decision
- HFRO
- FDMT Strong Buy
- Analyst Count
- HFRO 0
- FDMT 9
- Target Price
- HFRO N/A
- FDMT $46.75
- AVG Volume (30 Days)
- HFRO 421.7K
- FDMT 804.9K
- Earning Date
- HFRO 01-01-0001
- FDMT 11-13-2024
- Dividend Yield
- HFRO 12.00%
- FDMT N/A
- EPS Growth
- HFRO N/A
- FDMT N/A
- EPS
- HFRO 1.23
- FDMT N/A
- Revenue
- HFRO $44,535,929.00
- FDMT $17,000.00
- Revenue This Year
- HFRO N/A
- FDMT N/A
- Revenue Next Year
- HFRO N/A
- FDMT $57.85
- P/E Ratio
- HFRO $5.50
- FDMT N/A
- Revenue Growth
- HFRO N/A
- FDMT N/A
- 52 Week Low
- HFRO $5.92
- FDMT $7.32
- 52 Week High
- HFRO $9.38
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- HFRO 28.33
- FDMT 50.43
- Support Level
- HFRO $5.34
- FDMT $7.32
- Resistance Level
- HFRO $5.54
- FDMT $8.74
- Average True Range (ATR)
- HFRO 0.11
- FDMT 0.48
- MACD
- HFRO -0.00
- FDMT 0.19
- Stochastic Oscillator
- HFRO 20.27
- FDMT 82.97
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.